Goldman Sachs analyst Paul Choi maintained a Buy rating on Soleno Therapeutics today and set a price target of $125.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Paul Choi has given his Buy rating due to a combination of factors related to Soleno Therapeutics’ potential in the market. He believes that Vykat XR, the company’s treatment for Prader-Willi syndrome, is poised to become a key therapy in this area, especially considering the lack of effective alternatives. Despite some concerns about the drug’s safety profile, Choi is confident that proper patient screening will mitigate these issues, allowing for strong adoption.
Furthermore, Choi sees additional growth opportunities with the anticipated launch of Vykat XR in major European markets, projecting higher peak sales than current market expectations. He also notes the potential for Soleno Therapeutics to expand the use of its core drug into other indications, including general obesity, which could enhance long-term growth prospects. Overall, Choi views Soleno as a company with solid fundamentals and significant market potential, warranting a Buy rating and a price target of $125.
According to TipRanks, Choi is a 4-star analyst with an average return of 7.9% and a 53.42% success rate. Choi covers the Healthcare sector, focusing on stocks such as Lantheus, Ascendis Pharma, and RegenXBio.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $120.00 price target.